Content overview
Benefits
Compliance
Applications
References
Product
Content
- Benefits
- Compliance
- Applications
- References
- Product
MACS GMP T Cell TransAct can be utilized in clinical applications for robust activation and expansion of human T cells. T Cell TransAct is a polymeric nanomatrix conjugated to humanized recombinant CD3 and CD28 agonists, ensuring efficient activation of T cells.
For complete regulatory notes click here.
Content overview
Benefits
Compliance
Applications
References
Product
By providing robust and effective GMP-compliant T cell activation, MACS GMP T Cell TransAct enables safe and streamlined clinical manufacturing for cell therapy.
The reagent delivers optimal T cell activation with a polymeric nanomatrix. For robust and reliable T cell proliferation, it facilitates serum-free T cell cultivation while maintaining consistently high cell expansion.
As shown in the graph, T cell activation was assessed by quantifying the expression of activation markers, CD25 and CD69, both in the absence and presence of MACS GMP T Cell TransAct. Remarkably, over 80% of the cells showed activation within two days when treated with TransAct, indicated in blue.
Clinical-scale expansion of transduced T cells is effective under cultivation conditions with or without human AB serum.
In both cases, cell numbers and viability remain high, even when measured for approximately two weeks. The synergistic combination of MACS GMP T Cell TransAct, TexMACS™ GMP Medium, and MACS® GMP Cytokines delivers an optimal engineered cell product independent of serum addition.
Compatible with CliniMACS Prodigy®, MACS GMP T Cell TransAct stimulates and activates CAR (Chimeric Antigen Receptor)T cells.
As part of the process T cells were stimulated with MACS GMP T Cell TransAct and transduced with two viral vectors encoding for GFP. Transduction of T cells with GFP vector resulted in strong GFP expression eleven days after gene engineering. To achieve long-term gene expression through stable genomic insertion, two types of gene transduction tools are commonly used: gamma-retroviral vectors (RV) or lentiviral vectors (LV).
The CliniMACS Prodigy T Cell Transduction (TCT) process supports transduction with both vectors. For easy integration of RV-based transduction into the automated workflow of the CliniMACS Prodigy TCT process, MACS® GMP Vectofusin®-1 enhances your viral transduction efficiency.
Stable activation of T cells can be observed by microscopic analysis.
The image depicts CD4+/CD8+ T cells enriched from a healthy donor and a melanoma patient activated by the use of MACS GMP T Cell TransAct reagent. After 72 hours, the cell clumps in both the healthy donor and the melanoma patient indicate proper activation of the T cells.
MACS GMP T cell TransAct is manufactured and tested under a quality management system (ISO 13485) and is in compliance with relevant GMP guidelines. It is designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of this product is compliant with the requirements laid down in the Ph.Eur. Chapter 5.2.12. Learn more about our MACS GMP Products.
Every production step takes place under strict safety regulations in our GMP-certified facility, which is equipped with state of the art production areas from class A to D. MACS GMP T Cell TransAct is bottled using a validated aseptical filling process, before being subjected to a rigorous quality control (QC) testing procedure, thus guaranteeing a safe and sterile product. Every processing step from development to production and QC testing is extensively documented.
MACS GMP T Cell TransAct is optimized for automated cell culture processes such as clinical-grade CAR T cell manufacturing with the CliniMACS Prodigy System.
This process allows fully automated labeling, enrichment, activation, transduction, and expansion of human T cells from patient material for production of gene-engineered T cells.
Automated T cell transduction, using MACS GMP T Cell TransAct reagent, meets the requirements for clinical cell manufacturing.
Lock, D. & Mockel-Tenbrinck, N. et al. (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 10: 914–925. https://doi: 10.1089/hum.2017.111
Successful CAR-T cell production in multiple clinical sites, with CliniMACS Prodigy System.
Maschan, M. et al. (2021) Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 12 (1): 7200. https://doi: 10.1038/s41467-021-27312-6
Feasibility of 27 CAR-T cell manufacturing products from individual patients, using CliniMACS Prodigy.
Castella, M. et al. (2020) Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial. Front. Immunol. 11: 482. https://doi.org/10.3389/fimmu
1 product found
|
You have previously chosen International as your location.
What do you want to do?